A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapyYongqian Shu, Lianke Liu, Jing Qian et al.|Drug Design Development and Therapy|2016Cited by 12
Diagnosis and management of urinary bladder paragangliomas: A Sino‐American‐European retrospective observational studyYingxian Pang, Jacques W.M. Lenders, Jing Zhang et al.|Clinical Endocrinology|2024Cited by 12
Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatmentShiyun Cui, Xiaofeng Chen, Yuting Ding et al.|npj Precision Oncology|2025Cited by 4
Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 GastrectomyJing Sun, Xiaofeng Chen, Shaohua He et al.|Journal of Carcinogenesis & Mutagenesis|2017Cited by 0